NEW ORLEANS – The first medical society guideline to comprehensively address all facets of primary prevention of cardiovascular disease put special emphasis on a team-based approach that takes into account each person’s social determinants of health. The guideline substantially dialed down prior recommendations on aspirin for primary prevention by calling for no use in people older than 70 years and infrequent use in those 40-70 years old.

The American College of Cardiology and the American Heart Association released their 2019 guideline on the primary prevention of cardiovascular disease during the annual meeting of the American College of Cardiology (J Amer Coll Cardiol. 2019 Mar 17. doi: 10.1016/j.jacc.2019.03.010).

The guideline is a “one-stop shop” that pulls together existing recommendations from the two organizations and combines it with some new recommendations that address issues such as aspirin prophylaxis, and the social setting of each person, said Donna K. Arnett, PhD, professor of epidemiology at the University of Kentucky, dean of the university’s College of Public Health, and co-chair of the guideline writing panel.

“We made the social determinants of health front and center. With many people, clinicians

Immunotherapy gaining ground for peanut allergy

BY MICHELE G. SULLIVAN
MDedge News

Immunotherapy is showing success in treating a condition that is both dangerous to millions and on the rise: peanut allergy.

James Baker, MD, a specialist in pediatric allergy and immunology, at Providence Health & Services, Lake Oswego, Ore., has embraced an innovative immunotherapy approach to peanut allergy in his clinic. He and his team have successfully treated several hundred children with a carefully constructed, evidence-based, and monitored protocol of incremental desensitization. Dr. Baker and his colleagues who take this approach will have plenty of patients in the future if the current trend in the development of peanut allergy continues.

At the 2017 meeting of the American Academy of Allergy, Asthma, and Immunology, pediatric allergy specialist Ruchi Gupta, MD, of Northwestern University, Chicago, who presented the results of a 1-year survey of about 53,000 U.S. households, suggested that peanut allergies in kids had jumped close to 21% since 2010 (Ann Allergy Asthma Immunol. 2017 doi: 10.1016/j.anai.2017.08.060).

Perception vs. reality

Dr. Donna K. Arnett said the new guideline combines ACC and AHA recommendations and acknowledges the importance of social settings of individual patients.
CV prevention guideline pulls back prior advice on aspirin use // continued from page 1

don't ask whether they have access
to healthy foods or a way to get to
the pharmacy. Asking about these
issues is step one toward helping
people address their social situation,
Dr. Arnett said while introducing
the new guideline in a press brief-
ing. The guideline recommends that
clinicians assess the social determi-
nants for each person treated for
cardiovascular disease prevention
using a screening tool developed
by the U.S. Centers for Medicare &
Medicaid Services and made avail-
able by the National Academy of
"No other guideline has high-
lighted the social determinants of
health," noted Erin D. Michos, MD,
associate director of preventive car-
diology at Johns Hopkins Medicine
in Baltimore, and a member of the
guideline-writing panel. Other over-
arching themes of the guideline are
its emphasis on the need for a team
of clinicians to deliver all the dispa-
rate and time-consuming facets of
care needed for comprehensive pri-
mary prevention of cardiovascular
disease, and its call for a healthy life-
style throughout life as foundations
“No other guideline has highlighted the social determinants of health,” noted Erin D. Michos, MD, associate director of preventive cardiology at Johns Hopkins Medicine in Baltimore, and panel member. For prevention, Dr. Michos said in a video interview.

With 48 recommendations, the guideline also deals with prevention issues such as a healthy diet and body mass, appropriate control of diabetes, smoking cessation, and control of blood pressure and cholesterol. The writing committee took the cholesterol and blood pressure recommendations directly from recent guidelines from the ACC and AHA in 2017 (blood pressure: J Amer Coll Cardiol. 2018 May;71[19]:e177-248) and 2018 (cholesterol: Circulation. 2018 Nov 10; doi: 10.1161/CIR.0000000000000625).

The other major, new recommendations in the guideline deal with aspirin use for primary prevention, which recently underwent a shake up with publication of results from several studies that showed less cardiovascular benefit and more potential bleeding harm from routine aspirin prophylaxis than previously appreciated. Among the most notable of these reports, which led to a class III recommendation – do not use – for aspirin in people more than 70 years old came from the ASPREE (Aspirin in Reducing Events in the Elderly) study (New Engl J Med. 2018 Oct 18;379[16]:1519-28). For those 40-70 years old, the recommendation is class IIb, worded as “might be considered for select adults.”

“Aspirin is appropriate “generally no, occasionally yes,” said Amit Khera, MD, guideline-panel member, and professor of medicine at the University of Texas Southwestern Medical Center in Dallas.

“Generally no, occasionally yes,” is aspirin appropriate for people in this age group, notably those at high risk for cardiovascular disease and also at low risk for bleeding, explained Amit Khera, MD, a guideline-panel member, and professor of medicine and director of preventive cardiology at the University of Texas Southwestern Medical Center in Dallas.

As a guideline for primary prevention, a prime target audience is primary care physicians, who would need to be instrumental in apply-
Primary prevention guideline: The top 10 takeaways

1. Most importantly, advise patients to maintain healthy lifestyle throughout life.
2. Use team-based care, and evaluate each person’s social determinants of health, the team-care approach, and the recommendations dealing with diet and other aspects of a healthy lifestyle.
3. Perform a 10-year atherosclerotic cardiovascular disease risk estimation on adults age 75 years or younger.
4. Advise patients to have a healthy diet and maintain normal weight.
5. Advise patients to engage in physical activity.
6. Manage type 2 diabetes appropriately.
7. Advise patients to stop smoking tobacco.
9. Prescribe statin treatment appropriately to reduce risk and low-density lipoprotein cholesterol levels.
10. Manage patients’ blood pressure to recommended levels, generally less than 130/80 mm Hg.

February *CHEST Physician* story on LDCT screening complication risk: Further reflections

We received several emails from our engaged readership about one of our front-page stories from the February issue. In brief, there were concerns raised about how *CHEST Physician* characterized the findings of the recent study by Huo et al. in *JAMA Internal Medicine*. On my repeat review of our story and the Huo manuscript, as well as several conversations with content experts both within and outside of CHEST, I agree that we did mischaracterize the findings in our write-up.

While the study was not necessarily poorly conducted, there were some methodological concerns that deserved more careful consideration before putting the findings into our publication. *CHEST Physician* Editorial Board member M. Patricia Rivera, MD, FCCP, and past CHEST President Gerard A. Silvestri, MD, MS, FCCP, have kindly put together a brief discussion of the potential problems with this paper.

For those of you who took the time to write in, thanks so very much!

**David A. Schulman, MD, FCCP**

*Editor in Chief, CHEST Physician*

The cover story of the February 2019 edition of *CHEST Physician* titled “In real-world setting, LDCT screen is linked to high complication risk” erroneously interpreted a study by Huo and colleagues recently published in *JAMA Internal Medicine*. The cover story states that "the study included 174,702 individuals who underwent an invasive diagnostic procedure as a result of abnormal findings on lung cancer screening and 169,808 control subjects," "the rates of complications associated with diagnostic procedures following LDCT for lung cancer screening were substantially higher than the rates reported in clinical trials of LDCT" and that the findings emphasize the importance of discussing the risk of adverse events and cost as part of the shared decision-making process before LDCT screening.

One wonders if the data reported by Huo and colleagues was skewed by the lens it was presented through or by the lens through which it was interpreted. Let us first elucidate that the study by Huo et al. in *JAMA Internal Medicine* was NOT a study of patients who underwent LDCT for lung cancer screening but rather a retrospective, database cohort study from 2008-2013 of patients within the age eligible for screening (age 55 to 77) WITHOUT lung cancer, who underwent similar invasive diagnostic procedures as those performed in the NLST in non-protocol-driven community practices.

Huo et al. hypothesized that the rates of complications after invasive diagnostic procedures observed among screen-eligible patients in the general population would be higher than those reported in the NLST and tested their hypothesis by estimating the complication rate of common invasive diagnostic procedures using data from a database of procedure codes. The database did not however, provide the clinical condition or indication for the procedures, define the number of procedures required to achieve a diagnosis, or define what was the most invasive procedure performed.

The authors followed patients for 1 year after their procedure and reported any complication that occurred during that period as related to that procedure. This is not the standard in reporting complications from diagnostic bronchoscopic or radiologic procedures or the inability to provide a less-invasive procedure that can still provide a diagnosis.

Although it is easy to be critical of large database analyses because of the inherent limitations associated with constructing cohorts that can provide meaningful data, we should not ignore the trends outlined in this article, particularly as the size of the cohort is substantial.

One cannot argue about the importance of discussing the risk of potential complications and cost as a part of the shared decision-making process before LDCT screening, but the increased rate of complications reported by Huo et al. should not be interpreted as the complication rate from lung cancer screening in real-world setting, for this is inaccurate and has potential to create additional barriers in lung cancer screening, already beset by barriers on multiple levels. Moreover, we must emphasize that discussions of potential risks and cost from diagnostic pulmonary procedures should not be isolated to lung cancer screening.

**M. Patricia Rivera, MD, FCCP**

*Professor of Medicine, Division of Pulmonary and Critical Care Medicine*  
*Co-Director, Multidisciplinary Thoracic Oncology Program*  
*Director, Multidisciplinary Lung Cancer Screening Program*  
*Medical Director, Bronchoscopy and PFT Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, NC*
Children were experiencing more allergic reactions to other foods too. Allergy to shellfish increased 7%. The data support what parents and clinicians have been anecdotally reporting for years now: Food allergies in children are on the rise and have been for 2 decades.

A pivotal trial introduced the notion of the benefit of early food introduction. Conducted in the United Kingdom, LEAP (Learning Early About Peanut Allergy) randomized 640 infants with severe eczema, egg allergy, or both, to either consume or avoid peanuts until 60 months of age. Among the 530 who initially had negative skin-prick peanut testing, peanut allergy developed in 13.7% in the avoidance group and 1.9% in the consumption group, a highly statistically significant difference ($P$ less than .001).

**The protocol**

In 2008, a group at Duke University, in Durham, N.C., headed by A. Wesley Burks, MD, published the first peanut oral immunotherapy (OIT) protocol (J Allergy Clin Immunol. 2009 Aug;124:286-91.e6). Tested in 28 children with a mean age of 5 years, the protocol consisted of three phases. On the initial escalation day, children started out with 0.1 mg of peanut protein, doubling the dose every 30 minutes as tolerated until a maximum dose of 50 mg, for a total ingestion of 99 mg. Next, there was an at-home build-up phase between appointments consisting of a dose escalation of 25 mg every 2 weeks until children reached 300 mg. Finally, the home-maintenance phase was a daily ingestion of 300 mg of peanut protein, the equivalent of about one peanut.

Almost all of the children experienced some reaction on the first day, mostly respiratory and gastrointestinal symptoms and itching. The risk of reaction decreased in each dosing phase. There were only a few serious reactions during the 8-week trial, with two children requiring epinephrine auto-injectors and one child with severe palpitations.

Dr. Baker said, "It's so important to choose the right patients, and also the right parents. They all have to be extremely motivated." Dr. Baker said.

Age is a critical factor, too. Younger immune systems are more malleable, but preverbal children can't communicate well enough to describe their reactions. The ideal age, Dr. Baker said is 4-8 years old. By the time many parents enter Dr. Baker's office, they're stuck in "helicopter mode," in a constant state of worry about accidental allergen exposure. But they're usually extremely motivated to stick with the program, especially when they learn that the incidence of serious adverse events is very, very low – about 4% in a case series Dr. Baker and Ms. Paul published, along with allergists at four other practices (J Allergy Clin Immunol Pract. 2014 Jan-Feb;1[1]:91-6).

The paper reviewed reaction and success rates in 352 children treated for peanut allergy. In all, they received 240,351 doses of peanut, peanut butter, or peanut flour. Most children experienced reactions during the treatment, but the majority were mild and transient (itching, rash, mild wheezing treated with bronchodilator). Overall, 85% of the children were able to reach the target maintenance dose.

**Immunotherapy products in the pipeline**

Results of a potentially pivotal phase 3 study were just released. PALISADE (Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization) randomized 551 adults and children with peanut allergy to AR101 or placebo for 12 months (Clinicaltrials.gov identifier: NCT02635776). Subjects had a 1-day initial dose escalation from 0.5 mg to 6 mg. This was followed by dose increases every 2 weeks, from 3 mg to 300 mg, and a 24-week maintenance phase with a 300-mg target.

At the end of the study, 67.2% in the active arm and 4% in the placebo arm were able to eat the target dose of at least 600 mg of peanut protein, without a consumption-limiting symptom.

Dr. Baker is a PALISADE coinvestigator, but he expresses a tempered view of the product, which is essentially the same thing he uses in his clinic. The results of PALISADE weren't as good as those he and his colleagues achieved in their clinical case review. He predicted that the approved treatment will be substantially more expensive than using food-grade peanuts.

The peanut desensitization protocol is absolutely not a one-person show, Dr. Baker said. Any practice that wants to enter the field has to provide 24/7-365 phone support, advice, and emergency counseling. "It's part art and part science," Dr. Baker said. "I am happy they are [conducting trials]." Dr. Baker said. "But it's costing millions of dollars, and it's only a peanut."
Subcutaneous immunotherapy appears dangerous for patients with severe, uncontrolled asthma

BY MITCHEL L. ZOLER
MDedge News

SAN FRANCISCO – Asthma that’s severe and uncontrolled when a patient receives subcutaneous immunotherapy appears to be the “major factor” causing higher-grade systemic reactions or death from this treatment, David I. Bernstein, professor of medicine at the University of Cincinnati.

The survey results identified seven SCIT-related fatalities over about a decade of surveillance. The most common risk factor among these cases was severe, uncontrolled asthma, prompting Dr. Bernstein to conclude that these patients should not receive SCIT. “If the asthma is well controlled, then SCIT is fine,” even if it had been severe before treatment, he said in an interview.

Other factors affecting SCIT safety based on the survey results included:

• Screening patients with an asthma history for current asthma symptoms and lung function before each injection. Survey results showed that while 86% of respondents screened for symptoms, only a third also checked lung function.
• Modifying the dose or stopping SCIT injections after a severe systemic reaction. Survey results showed that more than a quarter of all systemic reactions and more than a third of grade 3 systemic reactions (severe anaphylaxis) happened following a prior systemic reaction. Dr. Bernstein called this “an important, modifiable risk factor.”
• Administering SCIT only in a setting staffed to manage a possible anaphylaxis episode, and adhere to at least a 30-minute observation period. “A key step is observing for at least 30 minutes, and giving epinephrine promptly when needed; the sooner the better,” Dr. Bernstein said. The percentage of practices that observe patients for at least 30 minutes has steadily improved during the decade that the survey has run.
• Modifying the SCIT dose in high-risk patients during the peak season for aeroallergens like pollen. Survey results showed that practices that did not adjust their SCIT dosages during peak pollen seasons had about double the rate of grade 3 or 4 systemic reactions, compared with practices that dialed down their dosages.
• Reducing SCIT dosages during an accelerated cluster buildup, a treatment approach that in general increases the risk for systemic reactions. Dr. Bernstein had no relevant disclosures.
PULMONOLOGY

Poor asthma control during pregnancy raises risk of preterm delivery

BY MITCHEL L. ZOLER
MDedge News

SAN FRANCISCO – Women with poorly-controlled asthma during pregnancy had a decreased rate of live births, and among the live births had a significantly increased rate of both preterm delivery and neonatal intensive care admissions, according to a review of insurance claims data for more than 1 million American women during 2011-2015.

On the other hand, asthma severity, which the researchers inferred based on the type and amount of treatment patients received, showed essentially no link with the live birth rate, Jennifer Yland said at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

“The findings add to the body of evidence that relate poor asthma control to an increased risk for pregnancy complications,” explained Michael X. Schatz, MD, an allergist at Kaiser Permanente of Southern California, in San Diego, and a co-author of the study.

Results from several prior studies had shown links between asthma and an increased rate of preterm birth, “but the larger, more generalizable population is a strength of the current findings. Results from prior studies have less frequently shown a link between asthma during pregnancy and neonatal ICU admissions,” he added. “The findings strengthen the case for good asthma control during pregnancy.”

For their review, Ms. Yland and her co-authors used insurance claims data from privately insured American women aged 12-55 years who were pregnant and had drug prescription records during the study period. The database included 996,861 women without an asthma diagnosis and 29,882 women diagnosed with asthma. The analysis excluded women diagnosed with chronic obstructive pulmonary disease at least twice during pregnancy.

To analyze the pregnancy outcomes by asthma severity Ms. Yland and her associates divided the asthma patients into five subgroups based on the drug regimens they were on during pregnancy as a surrogate marker of disease severity. This analysis showed no relationship between disease severity and live birth rate.

The researchers also ran an analysis that divided patients into the quality of their management during pregnancy – either good or poor – based on either of two markers of poor control: filling five or more prescriptions for a short-acting beta-antagonist, or at least one exacerbation episode defined as an asthma-related emergency department visit, hospitalization, or need for oral corticosteroid treatment. By these criteria 7,135 (24%) of the pregnant women with asthma were poorly controlled. The live birth rate was 74% among women without asthma, 71% among those with well-controlled asthma, and 68% among women with poorly-controlled asthma, reported Ms. Yland, a researcher at the Harvard T.H. Chan School of Public Health in Boston.

In a multivariate analysis that adjusted for demographic differences and comorbidities, women with poorly-controlled asthma had preterm delivery a statistically significant 30% more often than did women with well-controlled asthma, and the rate of neonatal ICU admissions was a significant 24% higher in women with poor-controlled asthma, compared with women who had well-controlled asthma. However, the rates of small-for-gestational-age infants and infants with congenital malformations was not significantly different between the well-controlled and poorly-controlled subgroups.

The finding that almost a quarter of the pregnant women in the study were poorly controlled wasn’t surprising, Dr. Schatz said in an interview. In some studies as many as half the asthma patients have poor control.

The 24% rate of poor asthma control during pregnancy in the studied women is “most likely an underestimate of poor control in the general population” because the study used data from women with commercial health insurance, noted Sonia Hernandez-Diaz, MD, lead investigator for the study and professor of epidemiology at Harvard T.H. Chan School of Public Health. “More disadvantaged populations, such as pregnant women on Medicaid, tend to have worse control.”

Barriers to good asthma control during pregnancy include smoking, weight gain, undertreatment, poor adherence, and viral infection. The overall approach to managing asthma during pregnancy is the same as when women are not pregnant, although certain asthma medications have a better safety record during pregnancy. “The most reassuring data exist for albuterol and inhaled steroids, particularly budesonide and fluticasone. reassuring data also exist for the long-acting beta-agonists salmeterol and formoterol, which are combined with inhaled steroids, and for montelukast,” Dr. Schatz said.

The study was funded by GlaxoSmithKline, and a co-author of the study is a company employee. Ms. Yland had no disclosures. Dr. Schatz has received research funding from ALK, AstraZeneca, Medimmune, GlaxoSmithKline, and Merck. Dr. Hernandez-Diaz has been a consultant to Boehringer Ingelheim, Roche, and UCB, and has received research funding from GlaxoSmithKline, Lilly, and Pfizer.

mzoler@mdedge.com


New IPF diagnostic test now covered by Medicare

BY LUCAS FRANKI
MDedge News

A new genomic classifier (Envisia), produced by Veracyte, has received final Medicare local coverage determination for the diagnosis of idiopathic pulmonary fibrosis (IPF).

The test is a complement to high-resolution CT that can help differentiate IPF from other interstitial lung diseases, as more than half of patients with IPF/interstitial lung disease report being misdiagnosed at least once. The test analyzes samples obtained through transbronchial biopsy, a nonsurgical procedure commonly used in lung evaluation. It has been shown to detect usual interstitial pneumonia, a signature of IPF, with high accuracy.

The new policy was issued through the Palmetto GBA MolDx program and will go into effect on April 1, 2019, making Envisia the first commercially available test of its kind, available to the 55 million people who are currently enrolled in Medicare.

“We are pleased that the evidence supporting the Envisia classifier met the MolDx program’s high standards for coverage. This important milestone will enable us to begin making the Envisia Classifier more widely available to patients with suspected IPF so that they can obtain an accurate, timely diagnosis and, in turn, appropriate treatment,” Bonnie Anderson, chairman and chief executive officer of Veracyte, said in a press release.

lfranki@mdedge.com
PULMONOLOGY

Daily aspirin users had fewer acute COPD flares

BY TARA HAELE
MDedge News

FROM JOURNAL CHEST® • Daily aspirin use could reduce the risk of acute exacerbations of chronic obstructive pulmonary disease, new data suggest.

Researchers reported the outcomes of an observational cohort study of 1,698 individuals with COPD, 45% of whom said they were taking daily aspirin at baseline. Their findings were published in Chest.

After a median follow-up of 2.7 years, aspirin users had an overall 22% lower incidence of acute COPD exacerbations compared with nonusers. This was largely accounted for by a 25% reduction in moderate exacerbations, but there was no significant difference between aspirin users and nonusers in severe exacerbations.

A similar pattern was seen after just 1 year of follow-up, with an overall 30% reduction in the incidence of exacerbations, a 37% reduction in moderate exacerbations, but no significant reduction in severe exacerbations.

"Though aspirin use has previously been linked with reduced mortality risk in patients with COPD, to our knowledge, this is the first study to investigate the association of daily aspirin use with respiratory morbidity in COPD," wrote Ashraf Fawzy, MD, of the division of pulmonary and critical care medicine at Johns Hopkins University, Baltimore, and his coauthors.

The association between aspirin use and reduced incidence of exacerbations was stronger among individuals with chronic bronchitis, which prompted the authors to suggest that future studies of aspirin in COPD should focus on participants with chronic bronchitis.

However, the association was not affected by COPD severity, emphysema presence or severity, or cardiometabolic phenotype.

Aspirin users reported better respiratory-specific quality of life than that of nonusers, including 34% lower odds of reporting moderate to severe dyspnea, and better baseline COPD health status.

"Findings of this study add to the existing literature by highlighting that aspirin use is also associated with reduced respiratory morbidity across several domains – including exacerbation risk, quality of life, and dyspnea – factors related to patient well-being and healthcare utilization," the authors wrote.

Aspirin users were more likely to be white, male, and obese, and less likely to be smokers. They had better lung function but more cardiovascular comorbidities at baseline, although the aspirin users and nonusers were matched on baseline characteristics.

Speculating on the mechanisms by which aspirin might impact COPD exacerbations, the authors noted that the drug has both systemic and local pulmonary mechanisms.

For example, a pathway that results in elevated levels of a urinary metabolite in patients with COPD is irreversibly blocked by aspirin. Aspirin also attenuates the elevation of inflammatory markers interleukin-6 and C-reactive protein, which are part of the inflammatory phenotype of COPD. Aspirin has been shown to reduce proinflammatory cytokines in the lung.

The authors did note that aspirin use was self-reported, so they did not have data on dosage or duration of use.

The National Institutes of Health funded the study. Six authors declared advisory board positions, research support, and other funding from the pharmaceutical sector. One author was also a founder of a company commercializing lung image analysis software. No other conflicts of interest were declared.


Algorithm ruled out acute PE in pregnant women

BY ANDREW D. BOWSER
MDedge News

A diagnostic algorithm adapted for use in pregnancy safely ruled out acute pulmonary embolism in nearly 500 women with suspected pulmonary embolism enrolled in a recent prospective study, investigators are reporting.

With the adapted algorithm, there was only one deep-vein thrombosis (DVT) and no pulmonary embolism (PE) in follow-up among those women, according to the investigators, including senior author Menno V. Huisman, MD, of the department of thrombosis and hemostasis at Leiden (Netherlands) University Medical Center and his coauthors.

The main advantage of the algorithm is that it averted CT pulmonary angiography in nearly 40% of patients, thus sparing radiation exposure to mother and fetus in many cases, the investigators added.

“Our algorithm provides solid evidence for the safe management of suspected PE in pregnant women, with selective use of CT pulmonary angiography,” Dr. Huisman and colleagues said in their March 21 report in the New England Journal of Medicine.

In a previous clinical trial, known as the YEARS study, a specialized diagnostic algorithm had a low incidence of failure in men and women with clinically suspected PE, as shown by a venous thromboembolism (VTE) rate of just 0.61% at 3 months and by use of CT pulmonary angiography that was 14 percentage points lower than with a conventional algorithmic approach.

For the current study, the investigators took the YEARS algorithm and adapted it for use in pregnant women with suspected PE presenting at 1 of 18 centers in the Netherlands, France, and Ireland.

Their adapted algorithm was based on the three criteria investigators said were most predictive in the YEARS trial, namely, clinical signs and symptoms of DVT, hemoptysis, and PE as the most likely diagnosis. Patients also underwent d-dimer testing, and if they had clinical signs and symptoms of DVT, underwent compression sonography of the symptomatic leg.

Pulmonary embolism was considered ruled out in patients who met none of the three YEARS criteria and had a d-dimer level of 480 ng/mL or less and so did not undergo CT pulmonary angiography.

"These data meet the proposed criteria for assessing the safety of diagnostic methods in VTE, even in the context of a low baseline prevalence of disease," the investigators wrote.

Overall, CT pulmonary angiography avoided potential radiation exposure-related harms in 39% of the patients, the investigators said, noting that the proportion of women avoiding the diagnostic test decreased from 65% for those evaluated in the third trimester, 46% in the second trimester, and 32% in the third.

The study was supported by unrestricted grants from Leiden University Medical Center and 17 other participating hospitals. Many authors reported financial ties to the pharmaceutical industry.

SNOWMASS, COLO. – Infective endocarditis in 2019 is very different from the disease most physicians encountered in training, both in terms of epidemiology and clinical presentation, Patrick T. O’Gara, MD, observed at the Annual Cardiovascular Conference at Snowmass sponsored by the American College of Cardiology.

The classic description of infective endocarditis provided by Sir William Osler, MD, was of a subacute bacterial infection characterized by a long latent phase of low-grade fever, back pain, weight loss, and night sweats. It was mainly a right-heart disease of younger individuals with an infected native valve, and the predominant pathogens were streptococci, Dr. O’Gara said.

“I think in the current era endocarditis is more often characterized by an acute illness with toxic features in the context of adults with a high burden of degenerative diseases – for example, patients with rheumatoid arthritis or psoriatic arthritis on immunosuppressive therapy, or diabetes, end-stage renal disease, and risk factors for hospital-acquired infection. Injectable drug use is through the roof; there’s a wider prevalence of cardiac implanted electronic devices, which are a wonderful place for bacteria to hide; and Staphylococcus aureus has certainly become the leading pathogen with regard to endocarditis in the United States, especially MRSA, often multidrug resistant,” said Dr. O’Gara, professor of medicine at Harvard Medical School, Boston.

“Also, no talk about endocarditis is sufficient without paying some attention to the opioid crisis in which we find ourselves. It’s one of the top three causes of death among young men in the United States, along with accidents and gun violence. No region of the country is spared. This has completely inundated our ER and hospitalist services and our inpatient cardiology services with folks who are often repeat offenders when it comes to the difficulty in being able to give up an injectable drug use habit. They have multiple infections and hospitalizations, tricuspid valve involvement, and depending upon the aggressiveness of the Staphylococcus organism, typically they have left-sided disease with multiple complications, including aortic regurgitation and heart failure,” the cardiologist continued.

This description underscored one of Dr. O’Gara’s major points about the challenges posed by infective endocarditis in contemporary practice: “Expect the unexpected,” he advised.

“When you’ve seen one case of infective endocarditis, you’ve seen one case of infective endocarditis.”

**Outcomes are ‘sobering’**

In the current era, outcomes are sobering,” the cardiologist noted. Infective endocarditis carries a 6-month mortality rate of 20%-25% despite early surgery being performed during the index hospitalization in up to 60% of patients, with a relatively high perioperative mortality rate of about 10%. However, the risk of reinfection occurring in a newly implanted cardiac valve is impressively low at about 2%.

**Refer early for multimodality imaging and surgical consultation**

Transesophageal echocardiography is valuable in assessment of the infected valve. However, when extra-valvular extension of the infection is suspected and the echo assessment is nondiagnostic or indeterminate, it’s time to quickly move on to advanced imaging, such as PET-CT.

The ACC/American Heart Association class I recommendations for early surgery in infected native valves haven’t changed substantially in over a decade. Based largely on observational data, there is an association between early surgery and lower in-hospital mortality (Lancet. 2012 Mar 10;379[9819]:965-75).

Class IIa recommendations for native valve surgery include recurrent emboli and a persistent vegetation despite appropriate antibiotic therapy. A “very controversial” class IIb recommendation for surgery because of weak supporting data is the identification of a mobile vegetation larger than 10 mm, particularly if it’s located on an anterior mitral valve leaflet, he said. If the decision is made to forgo early surgery, be sure to repeat transesophageal echocardiography on day 7-10 to reassess the size of the patient’s vegetation.

“There is an association between size of vegetation and 1-year mortality, with a cut point of greater than 15 mm. Some would argue this constitutes a reasonable indication for early surgery,” Dr. O’Gara noted.

The embolization rate in patients with infective endocarditis is highest during the day before presentation, the day of presentation, and through the first 2 days afterward. The rate drops precipitously within 2 weeks after initiation of appropriate antibiotic therapy. Thus, to utilize early surgery to maximum effect in order to decrease the risk of embolization, it makes sense to operate within the first several days following presentation, before antibiotics have had sufficient time to catch up with the evolving disease process.

**Removal of cardiac implanted electronic devices**

The guidelines are clear regarding infected pacemakers, implanted cardioverter defibrillators, and cardiac resynchronization devices: “It all needs to come out,” Dr. O’Gara emphasized. That includes all leads and the generator in patients with documented infection of only one portion of the device system, as a class I, level of evidence B recommendation. Moreover, complete removal of a pacemaker or defibrillator system is deemed “reasonable” as a class IIa recommendation in all patients with valvular infection caused by S. aureus or fungi even in the absence of evidence of device infection.

“I think we as general cardiologists have become increasingly impressed about how sick and festering these kinds of patients can become, even when we’re not able to prove that the lead is infected. The lead looks okay on transesophageal echo or PET-CT, blood cultures are negative, the valvular heart disease is really not that advanced, but several days go by and the patient is just not responding. We should have a high index of suspicion that there’s an infection we cannot appreciate. But obviously, you make these difficult decisions in consultation with your electrophysiology colleagues,” he added.

**Know when to say ‘no’ to early aggressive surgery**

While an aggressive early surgical approach often pays off in terms of prevention of embolic sequelae and a reduction in heart failure, the timing of surgery in the 20%-40% of patients with infective endocarditis who present with stroke or other neurologic complications remains controversial. An international group of Canadian and French cardiac surgeons and neurologists developed a useful algorithm regarding the types of neurologic complications for which early cardiac surgery is a poor idea because of the high risk of neurologic exacerbation. For example, a mycotic neuroaneurysm is grounds for postponement of cardiac surgery for at least 4 weeks (Circulation. 2016 Oct 25;134[17]:1280-92).

Dr. O’Gara reported receiving funding from the National Heart, Lung, and Blood Institute, the National Institute of Dental and Craniofacial Research, from Medtronic in conjunction with the ongoing pivotal APOLLO transcatheter mitral valve replacement trial, and from Edwards Lifesciences for the ongoing EARLY TAVR trial.

bjancin@mdedge.com
This advertisement is not available for the digital edition.
Before you refer for AFib ablation, educate your patient

BY BRUCE JANCIN
MDedge News

SNOWMASS, COLO. – Appropriate counseling before making a referral for atrial fibrillation ablation entails helping the patient understand what can realistically be expected in the way of benefit, along with instilling awareness of the warning signals heralding serious late complications, Samuel J. Asirvatham, MD, said at the Annual Cardiovascular Conference at Snowmass sponsored by the American College of Cardiology.

“Who to steer toward ablation? You have to have a symptomatic patient – that’s a given. For the ones who are paroxysmal, the ones with a relatively normal heart, there’s a much better chance that you’ll help manage their symptoms with ablation than if they have persistent or permanent AFib. Notice I do not use the word ‘cure’ for AFib. We talk about controlling symptoms and decreasing frequency, because the longer follow-up you have with intensive monitoring, the more you realize that patients still tend to have some AFib,” explained Dr. Asirvatham, an electrophysiologist who is professor of medicine and pediatrics at the Mayo Clinic in Rochester, Minn.

The rationale for early atrial fibrillation (AFib) ablation in younger patients with troublesome symptoms of paroxysmal AFib despite pharmacologic attempts at rate or rhythm control is that it will arrest the progression from an atrial arrhythmia that has just a few triggers readily neutralized by pulmonary vein isolation to persistent AFib with a diseased heart and a multitude of arrhythmia trigger points coming from many directions.

A solid candidate for ablation of paroxysmal AFib has about a 75% likelihood of having a successful first ablation procedure, with substantial improvement in symptoms and no need for medication. Another 9%-10% will achieve marked reduction in symptom burden upon addition of antiarrhythmic agents that weren’t effective before ablation.

Late complications can be deceptive

Periprocedural stroke/transient ischemic attack, tamponade, or bleeding on the table are infrequent complications readily recognized by the interventionalist. More problematic are several late complications which are often misinterpreted, with the resultant delay causing major harm.

• **Pulmonary vein stenosis.** This complication of inadvertent ablation inside the pulmonary vein manifests as shortness of breath, typically beginning about 4 weeks post ablation.

  “This is very different from the shortness of breath they had with atrial fibrillation. They almost always have a cough that they didn’t have before, and they may have hemoptysis. It’s very important to recognize this promptly, because before it closes completely we can do an angioplasty and stent the vein with good results. But once it closes completely, it becomes an extremely complicated procedure to try to reopen that vein,” according to Dr. Asirvatham.

  Very often the patient’s general cardiologist, chest physician, or primary care physician fails to recognize what’s happening. He cited an example: He recently had a patient with a cough who was first referred to an infectious disease specialist, who ordered a bronchoalveolar lavage. The specimen grew atypical actinomycetes. That prompted a referral to thoracic surgery for an open-lung biopsy. But that procedure required cardiac clearance beforehand. It was a cardiologist who said, “Wait – all this started after you had an ablation?”

  “That patient had pulmonary vein stenosis. And, unfortunately, that complication has not gone away. Being a referral center for pulmonary vein isolation, we see just as many cases of pulmonary vein stenosis today as we did a few years ago,” he said.

• **Atrial esophageal fistula.** The hallmark of this complication is onset of a plethora of what Dr. Asirvatham called “funny symptoms” more than a month post ablation. These include fever, transient ischemic attacks (TIAs), sepsislike symptoms, discomfort in swallowing, and in some cases hemoptysis.

  “The predominant picture is endocarditis/TIA/stroke. If you see this, and the patient has had ablation, immediately refer to surgery to have the fistula between the esophagus and heart fixed. This is not a patient where you say, ‘Nothing by mouth, give some antibiotics, and see what happens.’ I can tell you what will happen: The patient will die,” the cardiologist said.

• **Atrial stiffness.** This typically occurs about a month after a second or third ablation procedure, when the patient develops shortness of breath that keeps worsening.

  “You think ‘pulmonary vein stenosis,’ but the CT scan shows the veins are wide open. Many of these patients will get misdiagnosed as having heart failure with preserved ejection fraction even though they never had it before. The problem here is the atrium has become too stiff from the ablation, and this stiff atrium causes increased pressure, resulting in the shortness of breath. Sometimes patients feel better over time, but sometimes it’s very difficult to treat. But it’s important to recognize atrial stiffness and exclude other causes like pulmonary vein stenosis,” Dr. Asirvatham continued.

• **Gastroparesis.** This occurs because of injury to the vagus nerve branches located at the top of the esophagus, with resultant delayed gastric emptying.

  “It’s an uncomfortable feeling of fullness all the time. The patient will say, ‘It seems like I just ate, even though I ate 8 hours ago.’ The electrophysiologist said. “Most of these patients will recover in about 6 months. They may feel better on a gastric motility agent, like a macrolide antibiotic. I personally have not seen a patient who did not feel better within 6-8 months.”

Novel treatment approaches

“Patients sometimes will ask you, ‘What is this ablation? What does that mean? You have to be truthful and tell them that it’s just a fancy word for burning,’” the electrophysiologist said.

Achievement of AFib ablation without radiofrequency or cryoablation, instead utilizing nonthermal direct-current pulsed electrical fields, is “the hottest topic in the field of electrophysiology,” according to Dr. Asirvatham.

These electrical fields result in irreversible electroporation of targeted myocardial cell membranes, leading to cell death. It is a tissue-specific intervention, so it’s much less likely than conventional ablation to cause collateral damage to the esophagus and other structures.

“Direct current electroporation has transitioned from proof-of-concept studies to three relatively large patient trials. This is potentially an important breakthrough because if we don’t heat, a lot of the complications of AFib ablation will probably decrease,” he explained.

Two other promising outside-the-box approaches to the treatment of AFib are autonomic nervous system modulation at sites distant from the heart and particle beam ablation without need for cardiac catheters.

“If you put electrodes everywhere in the body to see where AFib starts, it’s not in the atrium, not in the pulmonary veins, it’s in the nerves behind the pulmonary veins, and before those nerves it’s in some other area of the autonomic nervous system. This has given rise to the notion that AFib may be an autonomic epilepsy of the heart,” according to the electrophysiologist.

This concept has given rise to a completely different approach to treatment of AFib through neurostimulation. Dr. Asirvatham reported having no financial conflicts regarding his presentation, although he serves as a consultant to a handful of medical startup companies and holds patents on intellectual property, the royalties for which go directly to the Mayo Clinic.
PEDIATRIC PULMONOLOGY

Palliative care has improved for critically ill children, but challenges remain

BY JIM KLING MDedge News

SAN DIEGO – Palliative care among critically ill pediatric patients in the intensive care unit is highly variable across institutions, and is more common among older children, female children, and those with government insurance or at a high risk of mortality. The findings come from a retrospective analysis of data from 32 hospitals, which included ICU admissions (except neonatal ICU) during 2007-2018.

The good news is that palliative care consultations have increased, with consultations in less than 1% of cases at the start of the study and rising quickly to more than 7% in 2018. “In the adult world, palliative care has expanded in recent decades, and I think now that it’s coming to the pediatric world, it’ll just continue to go up,” said Siobhan O’Keefe, MD, in an interview. Dr. O’Keefe is with Children’s Hospital Colorado, Aurora. She presented the study at the Critical Care Congress sponsored by the Society of Critical Care Medicine.

More work needs to be done, she said. “We are not uniformly using palliative care for critically ill children in the U.S., and it varies across institutions. That’s probably not the ideal situation,” said Dr. O’Keefe. The study did not track palliative care versus the presence of board-certified palliative care physicians or palliative care fellowships, but she suspects they would correlate.

Dr. O’Keefe called for physicians to think beyond the patient, to family members and caregivers. “We need to focus on family outcomes, how they are taking care of children with moderate disability, and incorporate that into our outcomes,” she said. Previous research has shown family members to be at risk of anxiety, depression, unemployment, and financial distress.

The researchers analyzed data from 740,890 patients with 1,024,666 hospitalizations (82% had one hospitalization). They divided subjects into three cohorts, one of which was a category of patients with criteria for palliative care based on previous research (PC-ICU). The PC-ICU cohort included patients with an expected length of stay more than 2 weeks, patients receiving extracorporeal membrane oxygenation (ECMO), severe brain injuries, acute respiratory failure with serious comorbidity, hematologic or oncologic disease, metabolic disease, renal failure that required continuous renal replacement therapy, hepatic failure, or serious chromosomal abnormality. A second cohort included chronic complex conditions not found in the PC-ICU cohort (additional criteria), and a third cohort had no criteria for palliative care.

Thirty percent of hospitalizations met the PC-ICU cohort criteria, 40% met the additional cohort criteria, and 30% fell in the no criteria cohort. The PC-ICU group had the highest mortality, at 8.03%, compared with 1.08% in the additional criteria group and 0.34% in the no criteria group (P less than .00001).

Palliative care consultations occurred more frequently in 5-12 year olds (odds ratio 1.06; 95% confidence interval, 1.01-1.13) and in those aged 13 years or older (OR, 1.38; 95% CI, 1.3-1.46), in females (OR, 1.13; 95% CI, 1.06-1.15), and in patients with government insurance (OR, 1.23; 95% CI, 1.17-1.29). Compared with those in the no criteria cohort, PC-ICU patients were more likely to receive a palliative care consult (OR, 75.5; 95% CI, 60.4-94.3), as were those in the additional criteria group (OR, 19.1; 95% CI, 15.3-23.9).

Cross-institutional palliative care frequency varied widely among patients in the PC-ICU group, ranging from 0% to 44%. The frequency ranged from 0% to 12% across institutions for patients in the additional criteria group.


Half of children with atopic dermatitis have sleep problems

BY HEIDI SPLETE MDedge News

Poor sleep quality, but not sleep duration, was significantly associated with active atopic dermatitis in a longitudinal study of more than 13,000 children.

The itching associated with atopic dermatitis (AD) may interfere with children’s sleep, and sleep studies suggest that children with active disease are more restless at night, wrote Faustine Ramirez of the University of California, San Diego, and her colleagues. Their report is in JAMA Pediatrics.

“Acute and chronic sleep disturbances have been associated with a wide range of cognitive, mood, and behavioral impairments and have been linked to poor educational performance,” the researchers noted.

To determine the impact of active AD on children’s sleep, the researchers reviewed data from 13,988 children followed for a median of 11 years. Of these, 4,938 children met the definition for AD between age 2 and 16 years.

Overall, children with active AD were approximately 50% more likely to experience poor sleep quality than were those without AD (adjusted odds ratio, 1.48). Sleep quality was even worse for children with severe active AD (aOR, 1.68), and active AD plus asthma or allergic rhinitis (aOR 2.15). Sleep quality was significantly worse in children reporting mild AD (aOR, 1.40) or inactive AD (aOR, 1.41), compared with children without AD. Nighttime sleep duration was similar throughout childhood for children with and without AD.

“In addition to increased nighttime awakenings and difficulty falling asleep, we found that children with active atopic dermatitis were more likely to report nightmares and early morning awakenings, which has not been previously studied,” Ms. Ramirez and her associates said.

Total sleep duration was statistically shorter overall for children with AD, compared with those without AD, but the difference was not clinically significant, they noted.

The participants were from a longitudinal study in the United Kingdom in which pregnant women were recruited between 1990 and 1992. For those with children alive at 1 year, their children were followed for approximately 16 years. Sleep quality was assessed at six time points with four standardized questionnaires between ages 2 and 10 years, and sleep duration was assessed at eight time points between ages 2 and 16 years with standardized questionnaires.

The study findings were limited by several factors, including some missing data and patient attrition, as well as possible misclassification bias because of the use of parent and patient self-reports, and a possible lack of generalizability to other populations, the researchers noted.

However, the results support the need for developing clinical outcome measures to address sleep quality in children with AD, they said. “Additional work should investigate interventions to improve sleep quality and examine the association between atopic dermatitis treatment and children’s sleep,” Ms. Ramirez wrote.

The study was funded primarily by a grant from the National Eczema Association. Ms. Ramirez disclosed a grant from the National Institutes of Health. Two other investigators received grants, one from NIH and the other Wellcome Senior Clinical Fellowship in Science. One coauthor reported receiving multiple grants, as well as paid consulting for TARGETPharma, a company developing a prospective atopic dermatitis registry.

Home oxygen therapy for children: New guidelines combine limited evidence, expert experience

BY ANDREW D. BOWSER
MDedge News

Based on the very limited evidence available, an expert panel convened by the American Thoracic Society has devised a clinical practice guideline specific to children who require home oxygen therapy.

The guideline authors not only addressed specific indications for chronic lung and pulmonary vascular diseases, but also defined hypoxemia in children — noting that Medicare and Medicaid coverage determinations for home oxygen therapy in children are based on decades-old studies that lacked pediatric patients — and offer expert advice on how to wean and discontinue oxygen, when warranted.

The disease-specific recommendations on whether or not to prescribe home oxygen therapy are characterized either as strong, meaning that it's the right course of action for at least 95% of patients; or conditional, meaning it might not be right for a “sizable minority” of patients, authors explained in the guideline.

Home oxygen therapy gets a strong recommendation, for example, in patients with cystic fibrosis complicated by severe chronic hypoxemia, but gets a conditional recommendation for sickle cell disease with severe chronic hypoxemia, according to the guideline, published in the American Journal of Respiratory and Critical Care Medicine.

Regardless of strong or conditional, the recommendations were largely based on "very low-quality evidence," according to ad hoc subcommittee of the ATS Assembly on Pediatrics, cochaired by Don Hayes Jr., MD, of Nationwide Children's Hospital, Columbus, Ohio; and Robin R. Deterding, MD, of Children's Hospital Colorado, Denver.

"Despite widespread use of home oxygen therapy for various lung and pulmonary vascular diseases, there is a striking paucity of data regarding its implementation, efficacy, monitoring, and discontinuation," Dr. Hayes, Dr. Deterding, and 20 additional committee members wrote in their report.

Accordingly, the panel sought to add expert opinion and experience to the limited evidence, in the hope that it would aid clinicians in the management of complex pediatric patients, they said.

One new tool they provide, toward that end, is a definition of hypoxemia in children based on oxygen saturation as quantified by pulse oximetry (SpO2).

Based on a review of 31 selected studies measuring oxygenation in healthy children, the expert panel defined hypoxemia (at or near sea level) as SpO2 of 90% or lower for 5% of the recording time in children under 1 year old, and an SpO2 of 93% or lower in older children; or alternatively, as three independent measurements of SpO2 less than or equal to 90% in the younger children and 93% in the older children.

By contrast, an SpO2 of less than 88% is one of the indications for funding home oxygen therapy as determined by the Centers for Medicare & Medicaid Services for both pediatric and adult patients, according to the committee.

The CMS indications derived from "seminal studies" showing that continuous oxygen therapy reduced mortality in adults with chronic obstructive pulmonary disease, they said in the guideline document.

"Despite the lack of pediatric patients in these historic studies performed over 35 years ago, the CMS coverage determination for [home oxygen therapy] is the same for pediatric patients of all ages compared with adult patients," they wrote in the report.

The committee unanimously agreed that 2 weeks of low SpO2 was "sufficient evidence" to indicate chronic hypoxemia, their report says.

Dr. Hayes reported no relationships with relevant commercial interests, while Dr. Deterding provided disclosures related to Boehringer Ingelheim, Novartis, and Elsevier Publishing, among others. Fellow committee members provided disclosures related to Shire Pharmaceuticals, United Therapeutics, and others as listed in the clinical practice guideline document.

AAP updates 2019-2020 flu vaccine recommendations to include nasal spray

BY CHRISTOPHER PALMER
MDedge News

Although the American Academy of Pediatrics had cited a preference for injected flu vaccines for children during the 2018-2019 flu season, this year's recommendations say either that or the nasal spray formulation are acceptable, according to a press release. The Centers for Disease Control and Prevention has given similar guidance.

Because the spray did not work as well against A/H1N1 as the injected vaccine had during the 2013-2014 and 2014-2015 seasons, the AAP did not recommend the spray during the 2015-2016 and 2016-2017 seasons. However, in 2017 the spray’s manufacturer included a new strain of A/ H1N1, and new data has supported the spray’s effectiveness against some strains.

The AAP recommends all children aged 6 months and older should be vaccinated, but the nasal spray is approved only for nonpregnant patients aged 2-49 years, according to the CDC.

That said, the spray is especially appropriate for patients who refuse to receive the injected form, so the choice of formulation is at the pediatrician’s discretion, according to the AAP release.

cpalmer@mdedge.com
We are at the leading edge of providing specialized care and extended recovery time for patients who require liberation from a mechanical ventilator.

Our physician-led interdisciplinary team provides ICU/CCU-level care and staffing when appropriate, pulmonary/critical care consultations, 24/7 respiratory therapy coverage and therapy consultations.

Every day, we help patients progress to a lower level of care while reducing costly readmissions.
Disruptive behavior on the job linked to depression, burnout

BY RANDY DOTINGA
MDedge News

SAN DIEGO – Hospitals pay a price for bad behavior by staff in the workplace, results of a large multicenter study suggest.

A work culture in which disruptive behavior is tolerated can have consequences. Research on this topic has linked disruptive behavior by staff in the health care setting to increased frequency of medical errors and lower quality of care (Am J Med Qual. 2011 Sep-Oct;26(5):372-9; J Caring Sci. 2016 Sep 1;5(3):241-9). This new study, based on a workplace culture survey of 7,923 health care workers and 325 work settings at 16 hospitals in a large West Coast health care system, found higher rates of depression and burnout among staff where disruptive behavior is prevalent, researchers found. The paper was presented by study lead Allison Hadley, MD, of Duke Children’s Hospital, Durham, N.C., at the Critical Care Congress sponsored by the Society of Critical Care Medicine.

The investigators developed a novel survey scale for evaluating disruptive behaviors in the health care setting. The objective was to look at the associations between disruptive behavior, teamwork, safety culture, burnout, and depression. Disruptive behaviors included turning backs or hanging up the phone before a conversation is over, bullying or trying to publicly humiliate others, making inappropriate comments (with sexual, racial, religious, or ethnic slurs), and physical aggression (such as throwing, hitting, and pushing).

San Francisco internist Alan H. Rosenstein, MD, who studies disruptive behavior in medicine, said in an interview that the findings confirm anecdotal experience of medical staff. "One of the downsides of disruptive behavior is very unsatisfying and unhappy people," he said.

The investigators used a t-test analysis to study the strength of the association between disruptive behavior and work culture in health care work settings. They found a statistically significant association between less disruptive behavior and lower levels of burnout and depression among staff (t = 6.4 and t = 4.1, respectively, P < .001) and higher levels of teamwork, safety culture, and work-life balance (t = 10.2, t = 9.5, and t = 5.8, respectively, P < .001). Settings in which disruptive behaviors were more common were more likely to have poor teamwork culture (P < .001) and safety climate (P < .001), and higher rates of depression (P < .001). Settings in which disruptive behaviors were more common were more likely to have poor teamwork culture (P < .001) and poor safety climate (P < .001), and higher rates of depression among staff (P < .001).

Bullying was reported at about 40% of workplaces with low teamwork levels, compared with nearly 20% in those with high teamwork levels.

Disruptive behaviors included turning backs or hanging up the phone before a conversation is over, bullying or trying to publicly humiliate others, making inappropriate comments (with sexual, racial, religious, or ethnic slurs), and physical aggression (such as throwing, hitting, and pushing).

Overall, the highest positive correlation was found between higher levels of teamwork and lower levels of disruptive behavior, Dr. Hadley said. If a hospital department is trying to address one issue to improve disruptive behavior, she'd suggest it "focus on teamwork first. I hope that would have the greatest impact."

No study funding was reported. Dr. Hadley and Dr. Rosenstein reported no relevant disclosures.

Updates from your CHEST Board of Regents

BY DAVID A. SCHULMAN
MD, FCCP

In late January, your Board of Regents met for its first face-to-face quarterly meeting under the leadership of new President Clayton Cowl, MD, MS, FCCP. One of the most valuable aspects of serving on the Board is an opportunity to take an overall look at the direction of the organization.

The Board makes a concerted effort not to get too deep into the weeds planning out specific tactics for achieving goals; we have a great many outstanding volunteers serving on dozens of our committees who do an incredible job of making things happen. The Board tries to focus on overall organizational strategy. Are we going in the right direction? Are there opportunities of which we should be taking better advantage? Are there efforts in which we are currently engaged that may not be yielding outcomes as we expected?

To better answer these questions, Dr. Cowl and his team asked all members of the Board of Regents and the Strategic Planning Subcommittee members of the Foundation Board of Trustees, as well as senior CHEST staff, to engage in an environmental scan to take an aggressive look at where we are and where we are headed. The output from our first environmental scan is currently being curated into a list of highest priority items that will be shared with the general membership in the coming months.

A review of our accomplishments over the last 6 months came next. Our new Executive Vice President and Chief Operating Officer, Dr. Robert Musacchio, has surpassed all expectations in his first few months in the role. In addition to continuing to push the organization toward the “One CHEST” model by better integrating the Foundation with the College, as well as refining our operating principles in working with industry, Bob is further developing our international reach—exploring collaborations with a number of large international societies and planning meetings abroad this year (CHEST Congress Thailand and CHEST Regional Congress Athens) and into the next (in Italy, with the regional meeting location to be determined).

We are also in the process of recruiting for a new position, Chief Learning Officer, a role that will serve not only to better organize the educational activities of CHEST, but also to serve as a visionary to better imagine what future projects we should be pursuing to be of better service and value to our members.

We took a few moments to recognize the new, incoming Editor in Chief of the journal CHEST®, Peter Mazzzone, MD, FCCP, will have some huge shoes to fill in taking the editor’s chair from Richard Irwin, MD, Master FCCP, who has served the journal in this role for more than a decade.

Under Dr. Irwin’s leadership, CHEST® journal has been the most-read publication amongst practicing pulmonary specialists; he is also responsible for having launched the journal’s social media presence, including both video series that integrated directly with the journal (such as Ultrasound Corner) and podcasts. Richard also spoke beautifully about his passion for patient-centered care as a keynote speaker at CHEST 2018.

Peter has outlined a number of different areas of focus for the journal in the next year, including putting a high priority on improving the reader experience and crafting an even better web and multimedia presence. We look forward to great things from the journal!

Chris Carroll, MD, FCCP, who chairs CHEST’s Digital Strategy Task Force, presented to the Board on their progress to date. The goal of this group is to evaluate the user experience for CHEST’s content delivery platforms, including the website, apps, and our social media platforms to identify opportunities for improvements that will enable us to better provide our members with on demand, high quality information to improve patient care through a personalized, seamless digital user experience.

The team is being co-led by Nicki Augustyn, Senior Vice President for Marketing, Communications, and Publishing, and Ron Moen, Chief Information Officer. We look forward to further updates on this important project.

As I stated in my opening, many of the good things that CHEST does can only happen with the participation of our great members, and so I want to take the time to recognize the NetWorks and everything that they do for the College. In the past year, under the leadership of Council of NetWorks Chairs Hassen Bencheqroun, MD, FCCP, and David Zielinski, MD, FCCP, the NetWorks produced more than 60% of the content at the 2018 CHEST meeting and are actively working on projects ranging from creating educational videos for public consumption to CHEST guidelines proposals and crafting a donor registry for lung transplantation. Our volunteer leaders are our most valuable resource; if you are not currently engaged in the NetWorks, please consider getting involved this spring during the nomination process!

It remains a privilege for the Board to serve this great organization. If you are interested in hearing more, or getting more engaged, please send me an email at chestphysiciannews@chestnet.org.

Welcoming a new Section Editor for Sleep Strategies

Michelle Cao, DO, FCCP, is a Clinical Associate Professor in the Division of Sleep Medicine and Division of Neuromuscular Medicine at the Stanford University School of Medicine. Her clinical expertise is in complex sleep-related respiratory disorders and home mechanical ventilation for chronic respiratory failure syndromes. She oversees the Noninvasive Ventilation Program for the Stanford Neuromuscular Medicine Center. Dr. Cao also holds the position of Vice-Chair for the Home-Based Mechanical Ventilation and Neuromuscular Disease Network with CHEST and is a member of the Scientific Presentations and Awards Committee.

CHEST thanks Dr. Chris Lettieri for his time and efforts as the previous Section Editor for Sleep Strategies.
Thank you to the CHEST 2019 Scientific Program Committee

BY WILLIAM F. KELLY, MD, FCCP

The CHEST 2019 Scientific Program Committee has been working tirelessly to select the best and most clinically relevant sessions for the upcoming meeting. CHEST would like to extend a heartfelt thank you to all who actively participated in grading, curriculum group calls, the live meeting in February, and all the homework in between. We’re not done, but your work has been instrumental in making the CHEST Annual Meeting 2019 a success.

Doreen J. Addrizzo-Harris, MD, FCCP
NYU School of Medicine

Olivier L. Axler, MD, PhD, FCCP
University of New Caledonia – Cardiology and Medical School

Susan J. Corbridge, PhD, ACNP
University of Illinois at Chicago

Bennett P. deBois-blanc, MD, FCCP
LSU Health New Orleans

Matthew J. Hegewald, MD, FCCP
LDS Hospital

William F. Kelly, MD, FCCP
Chair, Scientific Program Committee
Uniformed Services University of the Health Sciences

Doreen J. Addrizzo-Harris, MD, FCCP
NYU School of Medicine

Olivier L. Axler, MD, PhD, FCCP
University of New Caledonia – Cardiology and Medical School

Susan J. Corbridge, PhD, ACNP
University of Illinois at Chicago

Bennett P. deBois-blanc, MD, FCCP
LSU Health New Orleans

Matthew J. Hegewald, MD, FCCP
LDS Hospital

William F. Kelly, MD, FCCP
Chair, Scientific Program Committee
Uniformed Services University of the Health Sciences
since the landmark ARMA trial, use of low tidal volume ventilation (LTVV) at 6 mL/kg predicted body weight (PBW) has become our gold standard for ventilator management in acute respiratory distress syndrome (ARDS) (Brower RG, et al. *N Engl J Med*. 2000;342[18]:1301). While other studies have suggested that patients without ARDS may also benefit from lower volumes, the recently published Protective Ventilation in Patients Without ARDS (PReVENT) trial found no benefit to using LTVV in non-ARDS patients (Simonis FD, et al. *JAMA*. 2018;320[18]:1872). Does this mean we let physicians set volumes at will? Is tidal volume (Vt) even clinically relevant anymore in the non-ARDS population?

Prior to the PReVENT trial, our practice of LTVV for patients without ARDS was informed primarily by observational data. In 2012, a meta-analysis comparing LTVV with “conventional” Vt (10-12 mL/kg IBW) in non-ARDS patients found that those given LTVV had a lower incidence of acute lung injury and lower overall mortality (Neto AS, et al. *JAMA*. 2012 308[16]:1651). While these were promising findings, there was limited follow-up poststudy onset, and the majority of included studies were based on a surgical population. Additionally, the use of Vt > 10 mL/kg PBW has become uncommon in routine clinical practice. How comparable are those previous studies to today’s clinical milieu? When comparing outcomes for ICU patients who were ventilated with low (≤7mL/kg PBW), intermediate (>7, but <10 mL/kg PBW), and high (≥10 mL/kg PBW) Vt, a second meta-analysis found a 28% risk reduction in the development of ARDS or pneumonia with low vs high, but the similar difference was not seen when comparing low vs intermediate groups (Neto AS, et al. *Crit Care Med*. 2015;43[10]:2155). This research suggested that negative outcomes were driven by the excessive Vt.

Slated to be the definitive study on the matter, the PReVENT trial used a multicenter randomized control trial design comparing target Vt of 4 mL/kg with 10 mL/kg PBW, with setting titration primarily based on plateau pressure targets. The headline out of this trial may have been that it was “negative,” in that there was no difference between the groups in the primary outcome of ventilator-free days and survival by day 28. However, there are some important limitations to consider before discounting LTVV for everyone. First, half of the trial patients were ventilated with pressure-control ventilation, the actual Vt settings were 7.3 (5.9 – 9.1) for the low group vs 9.1 (7.7 – 10.5) mL/kg PBW for the intermediate group by day 3, statistically significant differences, but perhaps not as striking clinically. Moreover, a secondary analysis of ARDSnet data (Amato MB, et al., *N Engl J Med*. 2013;372[8]:747) also suggests that driving pressure, more so than Vt, may determine outcomes, which, for most patients in the PReVENT trial, remained in the “safe” range of < 15 cm H₂O. Finally, almost two-thirds of patients eligible for PReVENT were not enrolled, and the included cohort had Pao₂/Fio₂ ratios greater than 200 for the 3 days of the study, limiting generalizability, especially for patients with acute hypoxemic respiratory failure.

When approaching the patient who we have determined to not have ARDS (either by clinical diagnosis or suspicion plus a low Pao₂/Fio₂ ratio as defined by PReVENT’s protocol), it is important to also consider our accuracy in recognizing ARDS before settling for the use of unregulated Vt. ARDS is often underrecognized, and this delay in diagnosis results in delayed LTVV initiation. Results from the LUNG SAFE study, an international multicenter prospective observational study of over 2,300 ICU patients with ARDS, showed that only 34% of patients were recognized by the clinician to have ARDS at the time they met the Berlin criteria (Bellani G, et al. *JAMA*. 2016;315[8]:788). As ARDS is defined by clinical criteria, it is biologically plausible to think that the pathologic process commences before these criteria are recognized by the clinician.

To investigate the importance of timing of LTVV in ARDS, Needham and colleagues performed a prospective cohort study in patients with ARDS, examining the effect of Vt received over time on the outcome of ICU mortality (Needham DM, et al. *Am J Respir Crit Care Med*. 2015;191[2]:177). They found that every 1 mL/kg increase in Vt setting was associated with a 23% increase in mortality and, indeed, increases in subsequent Vt compared with baseline setting were associated with increasing mortality. One may, therefore, be concerned that if we miss the ARDS diagnosis, the default to higher Vt at the time of intubation may harm our patients. With or without clinician recognition of ARDS, LUNG SAFE revealed that the average Vt for the patients with confirmed ARDS was 7.6 (95% CI 7.5-7.7) mL/kg PBW. While this mean value is well within the range of lung protective ventilation (less than 8 mL/kg PBW), over one-third of patients were exposed to larger Vt. A recently published study by Sjödén and colleagues showed that Vt of >8 mL/kg PBW was used in 40% of the cohort, and continued exposure to 24 total hours of these high Vt values was associated with increased risk of mortality (OR 1.82 (95% CI, 1.20–2.78) (Sjödén MW, et al. *Crit Care Med*. 2019;47[1]:56). All three studies support early administration of lung protective ventilation, considering the high mortality associated with ARDS.

Before consolidating what we know about empiric use of LTVV, we also must highlight the important concerns about LTVV that were investigated in the PReVENT trial. Over-sedation to maintain low Vt, increased delirium, ventilator asynchrony, and possibility of effort-induced lung injury are some of the potential risks associated with LTVV. While there were no differences in the use of sedatives or neuromuscular blocking agents between groups in the PReVENT trial, more delirium was seen in the LTVV group with a P = .06, which may be a signal deserving further exploration.

Therefore, now understanding both the upside and downside of LTVV, what’s our best approach? While we lack prospective clinical trial data showing benefit of LTVV in patients without ARDS, we do not have conclusive evidence to show its harm. Remembering that even intensivists can fail to recognize ARDS at its onset, default utilization of LTVV, or at least lung protective ventilation of <8 mL/kg PBW, may be the safest approach for all patients. To be clear, this approach would still allow for active physician decision-making to personalize the settings to the individual patient’s needs, including the use of higher Vt if needed for patient comfort, effort, and sedation needs. Changing the default settings and implementing friendly reminders about how to manage the ventilator have already been shown to be...

We must also consider the process of health-care delivery and the implementation of best practices, after considering the facilitators and barriers to adoption of said practices. Many patients decompensate and require intubation prior to ICU arrival, with prolonged boarding in the ED or medical wards being a common occurrence for many hospitals. As such, we need to consider a ventilation strategy that allows for best practice implementation at a hospital-wide level, appealing to an interprofessional approach to ventilator management, employing physicians outside of critical care medicine, respiratory therapists, and nursing. The PReVENT trial had a nicely constructed protocol with clear instructions on ventilator adjustments with frequent plateau pressure measurements and patient assessments. In the real world setting, especially in a non-ICU setting, ventilator management is not as straightforward. Considering that plateau pressures were only checked in approximately 40% of the patients in LUNG SAFE cohort, active management and attention to driving pressure may be a stretch in many settings.

Until we get 100% sensitive in timely recognition (instantaneous, really) of ARDS pathology augmented by automated diagnostic tools embedded in the medical record and/or incorporate advanced technology in the ventilator management to avoid human error, employing simple defaults to guarantee a protective setting in case of later diagnosis of ARDS seems logical. We can even go further to separate the defaults into LTVV for hypoxic respiratory failure and lung protective ventilation for everything else, with future development of more algorithms, protocols, and clinical decision support tools for ventilator management. For the time being, a simpler intervention of setting a safer default is a great universal start.

Dr. Mathews and Dr. Howell are with the Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine; Dr. Mathews is also with the Department of Emergency Medicine; Icahn School of Medicine at Mount Sinai, New York, NY.

Sleep: It Does a Body Good by Dr. Nancy Stewart

Sleep: it does a body good. No really, it does. When asked to write this month’s blog on sleep for Sleep Awareness Month, although honored, it was somewhat comical because the night prior I had one of my worst nights of sleep in a long time, taking care of a sick child. As health-care providers, we often lead stressful lives and pack way too much into our schedules. Both the Centers for Disease Control and Prevention and the American Academy of Sleep Medicine recommend obtaining 7 to 9 hours of sleep per night for adults; unfortunately, many of us are not getting the recommended 7 to 9 hours of sleep. Find the entire blog at www.chestnet.org/News/Blogs.

Check out the current CHEST Thought Leaders Blog

INDEX OF ADVERTISERS

AstraZeneca 38-41
Genentech USA, Inc. 2-5
GSK group of companies 23-30, 48
Kindred Healthcare, LLC 33
Mylan Specialty L.P 13-14
Pfizer Inc. 9-11
Sanofi and Regeneron Pharmaceuticals, Inc. 17-21

2019 Education Calendar

May 3 - 4 Bronchoscopy Procedures for the ICU
May 30 - June 1 Advanced Critical Care Echocardiography
June 6 - 8 Difficult Airway Management
June 28 - 29 Therapeutic Bronchoscopy for Airway Obstruction
July 25 - 27 Mechanical Ventilation: Advanced Critical Care Management
August 8 - 10 Cardiopulmonary Exercise Testing (CPET)
September 5 - 7 Difficult Airway Management
September 12 - 14 Ultrasonography: Essentials in Critical Care
September 19 - 21 Comprehensive Bronchoscopy With Endobronchial Ultrasound
November 7-9 Extracorporeal Support for Respiratory and Cardiac Failure in Adults
November 14 - 16 Critical Care Ultrasound: Integration into Clinical Practice
November 22 - 23 Comprehensive Pleural Procedures
December 5 - 7 Ultrasonography: Essentials in Critical Care
December 13 - 14 Advanced Critical Care Echocardiography Board Review Exam Course
Social media for physicians: Strong medicine or snake oil?

BY HASSAN BENCHEQROUN, MD, FCCP

For most of us, social media is a daunting new reality that we are pressured to be part of but that we struggle to fit into our increasingly demanding schedules. My first social media foray as a physician was a Facebook fan page as a hobby rather than a professional presence. Years later, I have learned the incredible benefit that being on social media in other platforms brought to my profession.

What's social media going to bring to my medical practice?
The days where physicians retreat to the safety of our offices to deliver our care, or to issue carefully structured opinions, or interactions with patients have made way for a more direct interaction. Social media has, indeed, allowed us to share more personal glimpses of our daily struggle to save lives, behind-the-scenes snapshot of ethical struggles in decision making, our difficulties qualifying patients for therapies due to insurance complications, or real-time addressing medical news and combating misinformation. Moreover, when patients self-refer, or are referred to my practice, they look me up online before coming to my office. Online profiles are the new “first impression” of the bedside manner of a physician.

Other personal examples of social media benefits include being informed of new publications, since many journals now have an online presence; being able to interact in real-time with authors; learning from physicians in other countries how they handled issues, such as shortage of critical medications; or earning CME, such as the Twitterchats hosted by CHEST (eg, new biologic agents in difficult to treat asthma, or patient selection in triple therapy for COPD). Social media for physicians: Strong medicine or snake oil?

What are influencers or thought leaders?
Influencers may even be rewarded for harnessing their reach to make money off advertising. One can easily see how it is powerful for a physician to become an influencer or a “thought leader,” not to make money but to expand their reach on social media to spread the correct information about diets, drugs, e-cigarettes, and vaccinations, to name a few.

Can social media get me in trouble?
In 2012, a survey of the state medical boards published by JAMA (2012;307[11]:1141) revealed that approximately 30% of state medical boards reported complaints of “online violations of patient confidentiality.” More than 10% stated they had encountered a case of an “online depiction of intoxication.”

What kind of trouble could I be exposed to?
Poor quality of information, damage to our professional image, breaches of patient privacy, violation of patient-physician boundary, license revoking by state boards, and erroneous medical advice given in the absence of examining a patient, are all potential pitfalls for physicians in the careless use of social media.

How can I minimize my legal risk when interacting online?
It has been suggested that a legally sound approach in response to requests for online medical advice would be to send a standard response form that: informs the inquirer that the health-care provider does not answer online questions; supplies offline contact information so that an appointment can be made, if desired; and identifies a source for emergency services if the
On your mark, get set, GO!
The NetWorks Challenge is now underway

We are so excited to once again host the NetWorks Challenge. During the next 3 months, you have the opportunity to be a Champion and make a donation to the CHEST Foundation. Every time you contribute, you can designate a NetWork of your choice to benefit from your gift. Each NetWork is eligible to receive travel grants to CHEST 2019 based on the amount raised.

Last year, we more than doubled the number of early career clinician travel grants to attend CHEST 2018. This year, we want to raise the bar again. Don’t delay, make a donation today by visiting chestfoundation.org/donate and be a Champion for your NetWork!

Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate.

Additionally, any contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal.

Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.

Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.

Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised and the NetWork with the highest participation rate, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois. Visit chestfoundation.org/nc for more detailed information!

Explore the Moderate to Severe Asthma Center of Excellence

Engage with CHEST and Medscape as they partner on the Moderate to Severe Asthma Center of Excellence, designed to support physicians in addressing the challenges of diagnosing and treating moderate to severe asthma.

Rotating content will include articles, videos, commentary, and news on diagnostic, therapeutic, and prevention strategies, including the latest research and breakthroughs. New content will be added often, so check back for updates.

JUST ADDED:
- Biology of Asthma and Bronchiectasis: A Primer [video]
- Treating Adolescents With Asthma to the Adult Model of Care [video]
- Unmasking the Culprit [video]
- Diagnosing Severe Asthma: Not as Easy as it Sounds [video]
- Bronchial Thermoplasty: A Viable Option for Severe Asthma [video]

Other current topics include:
- Asthma Redefined: Managing Multiple Diseases
- Asthma Management in the Workforce and School Setting
- Asthma Management in the Workplace: Preventing Asthma Exacerbations

For more information about the 2019 grants cycle, contact Andrew Gillen at agillen@chestnet.org.
Black lung disease in the 21st century

Inhalation and deposition of coal dust particles cause a range of lung injury from coal workers’ pneumoconiosis (CWP) to dust-related diffuse fibrosis to COPD. Despite workplace standards and improved environmental controls to limit dust exposure within coal mines, incidence of “black lung disease” in the United States has increased since the turn of the century (Antao VC, et al. Occup Environ Med. 2005;62[10]:670).

Coal miners working in the Appalachian Mountains have been particularly vulnerable to developing rapidly progressive and severe pneumoconiosis. In 2018, three black lung clinics in central Appalachia uncovered the largest cluster of progressive massive fibrosis (PMF) ever reported (Blackley DJ, et al. JAMA. 2018;319[5]:500).

An investigation by National Public Radio (NPR) and the Public Broadcasting Service (PBS) program Frontline identified more than 2,000 Appalachian coal miners suffering with PMF from 2011 to 2016, while only 99 cases of PMF were identified by the current federal monitoring program during the same period (https://goo.gl/ZJXp1W).

Only about one-third of coal miners may participate in screening for black lung disease, and lack of participation could result from barriers such as fear of retaliation from employers (Siddons A. CQ-Roll Call, Inc. March 1, 2019; https://goo.gl/5mVFv).

Ongoing research is studying factors leading to the resurgence in CWP. Increasing silica content in coal dust is a likely culprit that has escaped mine safety regulations. Given the rising incidence and the increasing morbidity and mortality of black lung disease, there is a need to educate and engage pulmonologists and others to improve surveillance and early recognition of the spectrum of coal-dust-related lung diseases to decrease morbidity and mortality among this vulnerable occupational group.

In medicine, we identify patients with their illness, “the septic patient,” or category, “the terminal patient” or “the DNR patient” (Altillio, et al. AAHPM Quarterly. 2013;14–18). We escape responsibility for adequate communication by adopting a language filled with anatomic and pharmaceutical references where we blame patients for their disease process, eg, “the patient failed extubation” or “the patient is noncompliant.” We tend to resort to medical jargon or terror language in order to achieve the desired outcome.

Never is this more evident than when discussing code status. In the ICU, when one hopes to “get the DNR,” it is not uncommon to hear the phrase, “If your heart stops, we would have to break all of your ribs, and that would be torture.”

While the data are clear on harm.

Continued on following page

NEW! CHEST SEEK™
Critical Care Medicine: 28th Edition

The latest SEEK study product straight from the critical care medicine board examination content blueprints is now available.

- Study for board and accreditation exams.
- Refresh your core knowledge.
- Earn CME credit and MOC points.
Use CHEST SEEK™ education to test and improve your clinical skills in recall, interpretation, and problem-solving. Case-based questions reflect the content of the board certification examinations. Available in print or in the online CHEST SEEK™ Library.

This month in the journal

CHEST®
Editor’s Picks

BY RICHARD S. IRWIN, MD, MASTER FCCP

Giants in Chest Medicine
David C. Zavala, MD, FCCP

Original Research
Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review
By K. R. Gillmeyer, et al.

Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated

With Distinct Survival
Time and Pulmonary Function Trajectory.
By M. L. Salisbury, et al.

The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial.
By Q. Ou, et al, on behalf of the SAVE investigators.

Print | chestnet.org/store
CHEST SEEK™ Library | seeklibrary.chestnet.org
Five things to do near the convention center in NOLA

While CHEST 2019 will have your days busy, don’t forget to find time to explore entertaining, cultural, and historic places around New Orleans. Grab your friends and colleagues for some fun, and try out a few of these places.

1. House of Blues New Orleans
If you’re already heading to the city known for jazz and blues, there’s no better place to experience that than the House of Blues New Orleans. Enjoy live music and great food under one roof. Be sure to check the House of Blues website as the annual meeting draws nearer to see which concerts and events will be happening in October.

2. Audubon Aquarium of the Americas
Located just north of the convention center, head over to the Audubon Aquarium of the Americas. During the fall and winter months, the aquarium has less traffic, which allows you to take in all the animals and exhibits at your own pace. See exhibits like the Great Maya Reef, a walk-through tunnel into a submerged Maya city of the Yucatan peninsula; the penguins, sea otters, or the sharks and rays in the 400,000-gallon Gulf of Mexico Exhibit.

3. Ogden Museum of Southern Art
Less than 5 minutes from the convention center, the Ogden Museum of Southern Art holds the largest and most comprehensive collection of southern art, including visual art, music, literature, and culinary heritage. If you’re in the city before or after the annual meeting, catch a guided tour on a Thursday afternoon. Tours are free with admission into the museum. Check their website for museum hours.

4. Escape My Room
Who doesn’t love a good escape room? At Escape My Room, look for clues and hints to help the DeLaporte family as you’re transported through history into the DeLaporte Family Museum. Bring your family or team in a group of up to eight, depending on the room, and see if you can solve the mystery.

5. A walking tour of the Garden District
Take a cable car a few stops to the Garden District, a historic neighborhood in New Orleans. This picturesque neighborhood showcases plantation-style mansions, streets separated by stretches of green parks, and the historic Lafayette Cemetery No. 1 and cable car line that runs along St. Charles Avenue. There are guided tours available, but you can also choose to take a self-tour of the area.

Dr. Markos

Dr. Tobias

Dr. Markos

Dr. Tobias

NEWS FROM CHEST
This advertisement is not available for the digital edition.